Tech Company Financing Transactions
Re-Vana Therapeutics Funding Round
Re-Vana Therapeutics closed a $11.9 million Series A investment round on 11/30/2022. Backers included Visionary Venture Fund, Co-FundNI and ExSight Ventures.
Transaction Overview
Company Name
Announced On
11/30/2022
Transaction Type
Venture Equity
Amount
$11,900,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the proceeds for the development of its novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD� and OcuLief® biodegradable drug delivery technologies and for the expansion of operations and development teams.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1027 South Dakota Ave
Tampa, FL 33606
USA
Tampa, FL 33606
USA
Phone
Website
Email Address
Overview
Re-Vana Therapeutics is a 2016 start-up based on a technology developed at Queen's University Belfast (QUB), Northern Ireland, UK. QUB has recently been recognized as the No. 1 university in the UK for their capacity to commercialize research*. The novel concept of photocrosslinking for ocular drug delivery was developed by Dr. Raj Thakur and his team.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael O'Rourke
Chief Scientific Officer
Clive Wilson
Co-Founder
Thakur Raghu
Browse more venture capital transactions:
Prev: 11/30/2022: Prismforce venture capital transaction
Next: 11/30/2022: Elephant Energy venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs